Shigella Sonnei 53G Human Infection Study in Kenyan Adults
Safety and Feasibility of a Shigella Sonnei 53G Controlled Human Infection Model in Kenyan Adults: a Dose Finding and Dose Verification Study
Sponsor: Johns Hopkins University
Listed as NCT05959616, this PHASE1 trial focuses on Shigellosis and remains actively recruiting participants. Sponsored by Johns Hopkins University, it has been updated 6 times since 2025, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
6 versions recorded-
Apr 2025 — Present [monthly]
Recruiting PHASE1
Status: Not Yet Recruiting → Recruiting
-
Sep 2024 — Apr 2025 [monthly]
Not Yet Recruiting PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Not Yet Recruiting PHASE1
-
Jun 2024 — Jul 2024 [monthly]
Not Yet Recruiting PHASE1
-
Dec 2023 — Jun 2024 [monthly]
Not Yet Recruiting PHASE1
▶ Show 1 earlier version
-
Aug 2023 — Dec 2023 [monthly]
Not Yet Recruiting PHASE1
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Johns Hopkins University
- KEMRI United States Army Medical Research Directorate-Kenya
- KEMRI-Wellcome Trust Collaborative Research Program
- Naval Medical Research Center
- PATH
- University of Oxford
- Walter Reed Army Institute of Research (WRAIR)
For direct contact, visit the study record on ClinicalTrials.gov .